폴리 앤 라드너 LLP는 신장 질환 치료제 개발 후기 단계에 있는 비상장 바이오제약 기업인 패스털리스 파마(Pathalys Pharma Inc.)의 1억 500만 달러 규모 시리즈 B 자금 조달에서 주간 투자자로서 TCG 크로스오버(TCGX)를 대리했습니다.
TCGX was joined by other notable investors including J.P. Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, and JPS Growth Investment Limited Partnership, with support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.
Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end-stage kidney disease (ESKD). Pathalys’ initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD.
TCGX is a health care investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients.
The Foley team was led by partners Louis Lehot, Brian Wheeler, and Lyman Thai and included partners Andrew Rawlins and Jeffrey Lomprey and associates Saige Gallop and Robin Zhang.
